Silence Therapeutics (SLN) Common Equity (2018 - 2026)

Silence Therapeutics (SLN) has 9 years of Common Equity data on file, last reported at $49.4 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 56.18% year-over-year to $49.4 million; the trailing twelve-month figure through Mar 2026 stood at $49.4 million (down 56.18% YoY), and the FY2025 full-year result was $62.3 million, down 53.51% from the prior year.
• Common Equity eased to $49.4 million in Q1 2026, from $62.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $156.8 million in Q1 2024 to a low of $21.2 million in Q4 2023.
• A 5-year average of $90.9 million and a median of $94.2 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 533.33% in 2024 and tumbled 56.18% in 2026, its largest moves.
• Tracing SLN's Common Equity over 5 years: stood at $25.9 million in 2022, then slipped by 18.26% to $21.2 million in 2023, then surged by 533.33% to $134.0 million in 2024, then plunged by 53.51% to $62.3 million in 2025, then decreased by 20.71% to $49.4 million in 2026.
• Business Quant data shows SLN's Common Equity at $49.4 million in Q1 2026, $62.3 million in Q4 2025, and $74.1 million in Q3 2025.